Institutional Biosafety Committee
Institutional Biosafety Committee (IBC) has the charge of reviewing and approving the biological safety of all Children's Hospital of Philadelphia's basic and clinical research activities involving recombinant and synthetic nucleic acid molecules, gene transfer to humans, the generation of transgenic animals, microorganisms, viruses, and cloning biological toxins. The Institutional Biosafety Committee (IBC) is responsible for:
- Formulation of policy and procedure related to the use of recombinant DNA and biohazardous agents including: human pathogens, human blood and body fluids, oncogenic viruses, and all other infectious agents.
- Review and approval of work involving the generation of recombinant DNA, gene therapy and the formation of transgenic animals, as mandated by the National Institutes of Health.
- Maintaining an updated register of biohazardous agents used within CHOP Research Institute facilities.
- Review and approval of the safe practices and procedures for work with potentially infectious materials and recombinant DNA. All potentially infectious materials and recombinant DNA to be used in the labs or by staff must be registered with and approved for use by the IBC.
- Overseeing the Institutional Review Entity (IRE) subcommittee for review of Dual Use Research of Concern (DURC).
The Institutional Biosafety Committee (IBC) reviews all work with recombinant DNA (rNDA) and biohazardous material, and potential DURC. If you are working with any rDNA or biohazardous material, it must be registered with the IBC.
For more information about the committee, please refer to the Institutional Biosafety Committee Charter.
All of the following material must be registered with the IBC:
- Human, animal and plant pathogens
- Bacteria (except for non-pathogenic e.coli)
- Oncogenic viruses
- Human blood, blood products, tissues and body fluids
- Infected animals and animal tissues
- Cultured cells (all human or nonhuman primate and potentially infectious agents these cells may contain)
- Allergens, i.e. fungal extracts
The National Institutes of Health (NIH) requires the registration of research involving generation of recombinant or synthetic nucleic acid molecules. This includes work with recombinant or synthetic nucleic acid molecules for gene therapy, creation of transgenic animals and creation of recombinant or synthetic nucleic acid molecules. The Children's Hospital of Philadelphia Research Institute also requires the registration of all biohazardous material.
Refer to the NIH Guidelines or contact the IBC office to determine if your work with recombinant or synthetic nucleic acid molecules or biohazards must be registered.
The Institutional Biosafety Committee (IBC) will launched eIBC on March 23rd, 2015. eIBC is an eResearch module where Investigators are able to register new IBC protocols, amendments and 3 year renewals electronically. Paper registration forms will no longer be accepted.
The data from all currently registered, active protocols has been migrated to the eIBC smartforms and is accessible to Investigators and study staff. As a reminder, the IBC reviews and approves work involving the use of recombinant DNA, biohazardous agents, human source material and biological toxins used within the Research Institute.
The IBC staff is available to assist you with any questions you may have. Dedicated IBC office hours will be held Tuesdays from 10-11am in CTRB 2002 and Thursdays 2-3 in CTRB 2002. The IBC staff are also available by email, phone or in person. For more information please contact the IBC [at] email.chop.edu (IBC Office).